The effect on survival of continuing chemotherapy to near death
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Background: Overuse of anti-cancer therapy is an important quality-of-care issue. An aggressive approach to treatment can have negative effects on quality of life and cost, but its effect on survival is not well-defined. Methods: Using the Surveillance, Epidemiology, and End Results-Medicare database, we identified 7,879 Medicare-enrolled patients aged 65 or older who died after having survived at least 3 months after diagnosis of advanced non-small cell lung cancer (NSCLC) between 1991 and 1999. We used Cox proportional hazards regression analysis, propensity scores, and instrumental variable analysis (IVA) to compare survival among patients who never received chemotherapy (n = 4,345), those who received standard chemotherapy but not within two weeks prior to death (n = 3,235), and those who were still receiving chemotherapy within 14 days of death (n = 299). Geographic variation in the application of chemotherapy was used as the instrument for IVA. Results: Receipt of chemotherapy was associated with a 2-month improvement in overall survival. However, based on three different statistical approaches, no additional survival benefit was evident from continuing chemotherapy within 14 days of death. Moreover, patients receiving chemotherapy near the end of life were much less likely to enter hospice (81% versus 51% with no chemotherapy and 52% with standard chemotherapy, P < 0.001), or were more likely to be admitted within only 3 days of death. Conclusions: Continuing chemotherapy for advanced NSCLC until very near death is associated with a decreased likelihood of receiving hospice care but not prolonged survival. Oncologists should strive to discontinue chemotherapy as death approaches and encourage patients to enroll in hospice for better end-of-life palliative care.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases
DEYO, R. (1992) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(92)90133-8 · Cited by 10,452 · cited 1×
“A Charlson comorbidity index (0, 1, or 2 or more) was calculated by using the algorithm described elsewhere [17-19].”
MethodEarly Palliative Care for Patients with Metastatic Non–Small-Cell Lung Cancer
Temel, J. S., Greer, J. A., Muzikansky, A., Gallagher, E. R., Admane, S., Jackson, V. A., Dahlin, C. M., Blinderman, C. D., Jacobsen, J., Pirl, W. F., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1000678 · Cited by 7,482
Reducing Bias in Observational Studies Using Subclassification on the Propensity Score
Rosenbaum, P. R., & Rubin, D. B. (1984) · Journal of the American Statistical Association · doi:10.1080/01621459.1984.10478078 · Cited by 3,082
Inoue, A., Kobayashi, K., Usui, K., Maemondo, M., Okinaga, S., Mikami, I., Ando, M., Yamazaki, K., Saijo, Y., Gemma, A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.7658 · Cited by 505 · cited 2×
“For example, the modern targeted therapy including an introduction of epidermal growth factor receptor (EGFR) inhibitors [38,39] may have changed the risk/benefit equation.”
Background
Cited by
Communication About Serious Illness Care Goals: A Review and Synthesis of Best Practices
Bernacki, R. E., & Block, S. D. (2014) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2014.5271 · Cited by 1,422
Masters, G. A., Temin, S., Azzoli, C. G., Giaccone, G., Baker, S., Brahmer, J. R., Ellis, P. M., Gajra, A., Rackear, N., Schiller, J. H., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.1342 · Cited by 850
Schnipper, L. E., Smith, T. J., Raghavan, D., Blayney, D. W., Ganz, P. A., Mulvey, T. M., & Wollins, D. S. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.8375 · Cited by 649
Chemotherapy Use, Performance Status, and Quality of Life at the End of Life
Prigerson, H. G., Bao, Y., Shah, M. A., Paulk, M. E., LeBlanc, T. W., Schneider, B. J., Garrido, M. M., Reid, M. C., Berlin, D. A., Adelson, K. B., et al. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.2378 · Cited by 645
Hanna, N., Johnson, D., Temin, S., Baker, S., Brahmer, J., Ellis, P. M., Giaccone, G., Hesketh, P. J., Jaiyesimi, I., Leighl, N. B., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.6065 · Cited by 643
Metadata
- Authors
- Saito, A. M., Landrum, M. B., Neville, B. A., Ayanian, J. Z., & Earle, C. C.
- Venue
- BMC Palliative Care
- Published
- 2011-09-21
- Volume
- 10
- Issue
- 1
- Pages
- 14-14
- ISSN
- 1472-684X (ISSN-L)
- OpenAlex
- W2103084101
- Cited by
- 155
- References
- 4
- FWCI
- 10.29
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The effect on survival of continuing chemotherapy to near death. https://app.cochat.ai/papers/10.1186/1472-684x-10-14
- The paper
- Saito, A. M., Landrum, M. B., Neville, B. A., Ayanian, J. Z., & Earle, C. C. (2011). The effect on survival of continuing chemotherapy to near death. BMC Palliative Care. https://doi.org/10.1186/1472-684x-10-14
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.